20/20 Biolabs, Inc.
AIDX· Nasdaq
AIDX20/20 Biolabs, Inc.
Filed May 20, 2026 · 10-Q · 50 days after period end · 0001213900-26-059542
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $353.38K | $553.82K |
| Net Income | -$2.17M | -$764.58K |
| EPS Diluted | -$0.28 | -$0.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
20/20 Biolabs, Inc. · CIK 1139685 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 20, 2026 · 50 d after period end
